- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT02469532
DANCE Partner: Inflammatory Biomarker Analysis by Femoropopliteal Revascularization Method and Treatment Outcomes
연구 개요
상세 설명
This is a prospective, multi-center, observational registry to document the baseline, 24-hour and 30-day inflammatory response and procedural outcomes out to 12 month follow-up after femoropopliteal angioplasty or atherectomy-based revascularization procedures.
- To observe the femoropopliteal revascularization outcomes post-angioplasty and/or atherectomy and to observe potential correlation between patency outcomes and the levels of MCP-1, C-reactive protein and MMP-9 from baseline to 24 hours and 30 days post-procedure.
- To provide a comparator dataset to the investigational DANCE trial, which has the same enrollment criteria as this observational trial but includes the investigational use of a local drug therapy to limit inflammation caused by mechanical revascularization.
연구 유형
등록 (실제)
연락처 및 위치
연구 장소
-
-
Arkansas
-
Little Rock, Arkansas, 미국, 72211
- Arkansas Heart Hospital
-
-
Louisiana
-
Bossier City, Louisiana, 미국, 7111
- Endovascular Technologies (Willis Knighton Medical Center)
-
-
Mississippi
-
Hattiesburg, Mississippi, 미국, 39401
- Hattiesburg Clinic
-
-
North Carolina
-
Raleigh, North Carolina, 미국
- Rex Hospital
-
-
Texas
-
New Braunfels, Texas, 미국, 78130
- Mission Research Institute
-
Palestine, Texas, 미국, 75801
- Palestine Regional Medical Center
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
샘플링 방법
연구 인구
설명
Inclusion Criteria:
Screening Criteria
- Male or non-pregnant female ≥18 years of age
- Rutherford Clinical Category 2-4
- Clinical diagnosis of PAD requiring revascularization, secondary to atherosclerosis affecting a lower limb.
- Patient is willing to provide informed consent and comply with the required follow up visits Procedural Criteria
- De novo or nonstented restenotic lesions >90 days from prior angioplasty and/or atherectomy, at least 3 cm from any previously placed stent or vascular surgery site
- >70% diameter stenosis up to 15 cm in total length (with no greater than 3 cm length of contiguous intervening normal artery) in the superficial femoral and/or popliteal artery (between the profunda and tibioperoneal trunk)
- Reference vessel diameter ≥3mm and ≤ 8mm
- Successful wire crossing of lesion
- A patent artery proximal to the index lesion free from significant stenosis (significant stenosis is defined as >50% in iliac or >30% stenosis in common femoral artery) as confirmed by angiography (treatment of target lesion after successful treatment of iliac or common femoral artery lesions is acceptable)
Exclusion Criteria:
Screening Criteria
- Pregnant, nursing or planning on becoming pregnant in < 2years
- Life expectancy of <2 years
- Known active malignancy
- History of solid organ transplantation
- Patient actively participating in another investigational device or drug study
- History of hemorrhagic stroke within 3 months
- Previous or planned surgical or interventional procedure within 30 days of index procedure
- Chronic renal insufficiency with eGFR <29
- Prior bypass surgery, drug-coated balloon or stenting of the target lesion
- Contra-indication or known hypersensitivity to contrast media or physician prescribed antiplatelet regimen as applicable
- Systemic fungal infection
- Anticipated use of IIb/IIIa inhibitor prior to index lesion treatment
- Acute or sub-acute thrombus, acute vessel occlusion or sudden symptom onset
- Acute limb ischemia
- Inability to ambulate (e.g. from prior ipsilateral or contralateral amputation)
- Patient is receiving steroids already, however locally acting inhaled steroids for asthma treatment do not exclude patients from the trial Procedural Criteria
- Lesions extending into the trifurcation or above the profunda
- Heavy eccentric or moderate circumferential calcification at index lesion
- Lesion length is >15 cm as measured from proximal normal vessel to distal normal vessel, or there is no normal proximal arterial segment in which duplex ultrasound velocity ratios can be measured
- Inadequate distal outflow defined as absence of at least one patent tibial artery (no lesion >50% stenosis) with flow into the foot
- Use of adjunctive therapies other than angioplasty, atherectomy (mechanical or laser) or bare metal stenting (i.e. scoring/cutting balloon, drug-eluting stent, drug-coated balloon, cryoplasty, etc.)
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
코호트 및 개입
그룹/코호트 |
개입 / 치료 |
|---|---|
|
Atherectomy
Up to 20 atherectomy procedures at up to 5 sites in the United States. Change in inflammatory biomarkers (hs-CRP, MCP-1 and MMP-9) from baseline to 24 hours post-procedure and 30-days post-revascularization procedure. This registry will also observe outcomes (target lesion revascularization rates, 6 and 12 month duplex ultrasound-detected binary restenosis with PSVR>2.4) post-atherectomy revascularization procedures. |
Device: Orbital or Directional or Laser Atherectomy Systems Atherectomy selection is driven by preference of the operator
|
|
Angioplasty
Up to 20 angioplasty procedures at up to 5 sites in the United States. Change in inflammatory biomarkers (hs-CRP, MCP-1 and MMP-9) from baseline to 24 hours post-procedure and 30-days post-revascularization procedure. This registry will also observe outcomes (target lesion revascularization rates, 6 and 12 month duplex ultrasound-detected binary restenosis with PSVR>2.4) post-angioplasty revascularization procedures. |
Device: Balloon Angioplasty Selection is driven by preference of the operator
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Change in inflammatory biomarkers
기간: Baseline to 24-hours post-procedure and 30-days post-procedure
|
Change in inflammatory biomarkers (hs-CRP, MCP-1 and MMP-9) from baseline to 24 hours post-procedure and 30-days post-revascularization procedure.
|
Baseline to 24-hours post-procedure and 30-days post-procedure
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Target Lesion Revascularization
기간: 6 and 12 months post-procedure
|
This registry will prospectively collect data from patients diagnosed with peripheral arterial disease to observe the restenosis rates in peripheral arteries compared with subjects enrolled in the DANCE trial (Mercator MedSystems TSP0149).
|
6 and 12 months post-procedure
|
|
Comparing biomarker (hs-CRP, MCP-1 and MMP-9) results
기간: Baseline to 24 hours post-procedure and 30-days post-revascularization procedure
|
This registry will prospectively collect data from patients diagnosed with peripheral arterial disease to observe the correlation between the levels of MCP-1, C-reactive protein and MMP-9 after angioplasty or atherectomy procedures in peripheral arteries compared with subjects enrolled in the DANCE trial (Mercator MedSystems TSP0149).
Objective measurement of biomarkers will be performed by a contract laboratory to avoid bias.
|
Baseline to 24 hours post-procedure and 30-days post-revascularization procedure
|
공동 작업자 및 조사자
수사관
- 수석 연구원: Jason A Yoho, MD, Mission Research, New Braunfels, TX
연구 기록 날짜
연구 주요 날짜
연구 시작
기본 완료 (실제)
연구 완료 (실제)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (추정)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .
말초 동맥 질환에 대한 임상 시험
-
C. R. Bard완전한
-
Mayo Clinic초대로 등록
-
University Hospital, Strasbourg, France완전한
-
University Hospital, Strasbourg, France아직 모집하지 않음에크모 | Venoven VV 또는 Veno-Arterial VA의 mplementation | 집중 치료프랑스
-
L2 Bio, LLCFDAMap; Akan Biosciences, Inc.아직 모집하지 않음Crohn & amp;#39; s | Crohn & amp;#39; s Disease (CD)
-
Vanderbilt University Medical CenterTakeda Pharmaceuticals U.S.A., Inc.모집하지 않고 적극적으로염증성 장질환(IBD) | 궤양성 대장염(UC) | Crohn & amp;#39; s Disease (CD)미국
-
Nandakumar NarayananNational Institute of Neurological Disorders and Stroke (NINDS)초대로 등록
-
UNC Lineberger Comprehensive Cancer CenterFogarty International Center of the National Institute of Health모집하지 않고 적극적으로
Atherectomy System에 대한 임상 시험
-
Boston Scientific Corporation모집하지 않고 적극적으로
-
SpineSave AG모병척추관절염 | 불안정성 요추 | 퇴행성 척추전방전위증 | 퇴행성 요추 척추 협착증 | 디스크파시 | 후관절 관절염스위스
-
SynchroHealth LLCUniversity of North Carolina, Chapel Hill아직 모집하지 않음
-
ReVivo Medical, Corp.The Cleveland Clinic; Albany Medical College; IGEA모병목 통증 | 척추증 | 척수병증을 동반한 척추증 | Radiculopathy를 동반한 척추증 | Radiculopathy 자궁 경부 영역을 동반한 척추증 | 추간판 장애 자궁 경부미국
-
CMR Surgical LtdUniwersyteckie Centrum Kliniczne im. prof. K. Gibińskego Śląskiego Uniwersytetu Medycznego...모병
-
Penumbra Inc.모병급성 허혈성 뇌졸중(AIS)호주, 독일, 프랑스, 스위스